Hemolytic uremic syndrome (HUS) is a multisystemic condition characterized by a triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. HUS can be classified as atypical or typical, depending upon its association with the Shiga toxin-producing Escherichia coli (STEC). Approximately 90-95% of cases are classified as typical, while only 5-10% of cases are atypical. The pathogenesis of atypical HUS (aHUS) occurs when the complement cascade is activated and causes membrane attack complex (MAC) deposition in the renal tubular epithelium. Various infectious triggers have been associated with aHUS. A new and compelling correlation to this rare and potentially deadly diagnosis of aHUS is COVID-19 infection or vaccination. We present a case of COVID-19-induced exacerbation of a patient with a known history of aHUS. In addition, we performed a literature review of previously reported COVID-19-induced aHUS cases and identified the potential pathogenesis of the disease state.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466298PMC
http://dx.doi.org/10.7759/cureus.27962DOI Listing

Publication Analysis

Top Keywords

hemolytic uremic
8
uremic syndrome
8
ahus
5
covid-19 rare
4
rare hemolytic
4
syndrome hemolytic
4
syndrome hus
4
hus multisystemic
4
multisystemic condition
4
condition characterized
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!